Replies to post #391489 on Anavex Life Sciences Corp (AVXL)

[frrol]

His first paragraph is another slide regurgitation, followed by a mistake:

1) ADAS-Cog score change of or better -0.50 @ 48 weeks is defined as a clinically significant change. Therefore, patients with an improvement of -0.50 were defined as improved. (A later slide shows the improvement of -1.85 overall for all patients treated)

The "later slide" does not show an "improvement of -1.85 overall for all patients treated" that can be judged against the -.50 threshold. The -1.85 is net delta to placebo, which is an 'improvement'. The -.50 threshold is improvement from baseline. He's mistakenly associating two different types of 'improvement' as if they're the same. In simpler terms, he's associating apples with oranges.